Table 3. Progression-free survival.

Analysis	Intervention	N	Median PFS (months)	95% CI for median PFS (months)	HR	95% CI for HR	P-value
AVOREN study (Escudier et al, 2008; Bracarda et al, 2007; Melichar et al, 2007; Escudier et al, 2007; Bajetta et al, 2008)
Interim	Bevacizumab plus IFN	327	10.2	—	0.63	0.52–0.75	<0.0001
	Placebo plus IFN	322	5.4	—
CALGB 90206 study (Rini et al, 2008)
Sixth interima	Bevacizumab plus IFN	369	8.5	7.5–9.7	0.71	0.61–0.83	<0.0001
	IFN	363	5.2	3.1–5.6
Sunitinib vs IFN phase III trial (Motzer et al, 2007b; Motzer et al, 2007c; Figlin et al, 2008; Motzer et al, 2007a; Motzer et al, 2006)
Second interim	Sunitinib	375	11b	10–12	0.42	0.32–0.54	<0.001
	IFN	375	5b	4–6
Interim data cut-off February 2007	Sunitinib	375	11b	10.7–13.4	0.538	0.439–0.658	<0000001
	IFN	375	5.1b	3.9–5.6
Censored finalc	Sunitinib	375	Not reported	Not reported
	IFN	375
Post hoc finald	Sunitinib	193	Not reported	Not reported
	IFN	162

Abbreviations: CI=confidence interval; HR=hazard ratio; IFN=interferon; OS=overall survival; PFS=progression-free survival.

^aEstimate of HR adjusted for stratification factors – nephrectomy status and MSKCC risk factors.

^bResults from independent review.

^cn=25 patients in the IFN group who crossed over to sunitinib.

^dIncludes only those patients who received no post-study treatment.